Activity Provided By:

Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Managing Myeloma: Where We Are, Where We’re Going, and Where We SHOULD Be Going (Time to Choose Sides!)

Overview / Abstract:	ACTIVITY DESCRIPTION In the last 17 years, clinicians and patients have witnessed significant advances in multiple myeloma (MM) management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease (MRD), and delivering supportive care. Even more remarkably, in this time 14 new drugs have been approved by the US Food and Drug Administration for use in MM. This expansion of MM management options brings both opportunities and challenges for oncology HCPs. Furthermore, the rapidity with which clinical data relating to MM therapy is evolving and emerging all but ensures that the MM treatment paradigm will continue to change significantly in the near future. This activity follows a debate format and features audience polling relating to the proffered arguments, as well as panel discussions. Educational Objectives Upon completion of this activity, participants should be better able to: - Evaluate emerging data regarding the approach to maintenance therapy based on MRD status - Describe the options available to patients who have relapsed from or are resistant to multiple prior therapies - Incorporate the use of novel agent/monoclonal antibody–based regimens for newly diagnosed or relapsed/refractory MM patients based on currently available evidence
Expiration	Jan 15, 2022
Discipline(s)	Nurse Practitioner , Physician CME, Physician Assistant CME
Format	Webinar / Webcast / Video
Credits / Hours	This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.Penn State College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation	ACCME
Presenters / Authors / Faculty	Hearn Jay Cho, MD, PhD—Program Co-Chair Chief Medical Officer Multiple Myeloma Research Foundation Norwalk, Connecticut Associate Professor Icahn School of Medicine at Mount Sinai New York, New York Paul G. Richardson, MD—Program Co-Chair R. J. Corman Professor of Medicine Harvard Medical School Clinical Program Leader and Director of Clinical Research Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston, Massachusetts A. Keith Stewart, MBChB, MRCP, FRCPC, MBA—Program Co-Chair Professor of Medicine University of Toronto Medical Director Princess Margaret Cancer Centre Vice President Cancer University Health Network Toronto, Ontario, Canada Adam D. Cohen, MD Associate Professor of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania Suzanne Lentzsch, MD, PhD Professor of Medicine Columbia University Medical College College of Physicians and Surgeons Columbia University Director, Multiple Myeloma and Amyloidosis Service New York Presbyterian Hospital/Columbia University Medical Center New York, New York David S. Siegel, MD, PhD Founding Director, Institute for Multiple Myeloma Hackensack Meridian Health Center for Discovery & Innovation Chief, Multiple Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack, New Jersey
Activity Specialities / Related Topics	Education / Teaching, Hematology, Oncology / Cancer / Radiation Therapy
Sponsors / Supporters / Grant Providers	Support for this activity has been provided through educational grants from Adaptive Biotechnologies Corporation; Amgen, Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc.; and Oncopeptides. The joint sponsors also wish to thank CURE and Targeted Oncology for their support.
Keywords / Search Terms	RedMedEd RedMedEd RedMedEd MMRF, MM, multiple myeloma, multiple myeloma research foundation, new strategies, diagnosis, assessing prognosis, monitoring, minimal residual disease, MRD, supportive care, new drugs, management, options, debate, treatment, Free, CME, CE, hematologist, hematology, oncology, clinical data, therapy Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map